Background: In this study, six enzyme-linked immunosorbent assays (ELISA), intended for routine porcine reproductive and respiratory syndrome virus (PRRSV) herd monitoring, are tested for their ability to detect PRRSV specific antibodies in the serum of pigs after vaccination with an inactivated PRRSV type 1 vaccine and subsequent infection with a highly pathogenic (HP) PRRSV field strain. For this reason, ten piglets (group V) from a PRRSV negative herd were vaccinated twice at the age of 2 and 4 weeks with an inactivated PRRSV vaccine. Ten additional piglets (group N) from the sameherd remained unvaccinated. Three weeks after second vaccination, each of the piglets received an intradermal application of an HP PRRSV field strain. Serum samples were taken before first vaccination as well as before and 3, 7, 10 and 14 days after HP PRRSV application. All serum samples were tested for PRRSV RNA by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) as well as for PRRSV antibodies with all six study ELISAs. Results: At the beginning of the study (before vaccination), all of the piglets were PRRSV antibody negative with all study ELISAs. They also tested negative for PRRSV RNA measured by RT-qPCR. From day 3 after HP PRRSV application until the end of the study, a viremia was detected by RT-qPCR in all of the piglets. On day 0 (day of HP PRRSV application), nine out of ten piglets of the pre-vaccinated group tested PRRSV antibody positive with one of the tested ELISAs, although with lower S/P values than after infection. On day 10 after HP PRRSV application, all study ELISAs except one had significantly higher S/P or OD values, respectively more positive samples, in group V than in group N. Conclusions: Only one of the tested ELISAs was able to detect reliably PRRSV antibodies in pigs vaccinated with an inactivated PRRSV vaccine. With most of the tested ELISAs, higher S/P values respectively more positive samples after PRRSV infection were seen in the pre-vaccinated group than in the non-vaccinated.

Die Organtransplantation stellt ein therapeutisches Verfahren für Patienten mit irreversibel geschädigten Organen dar. Doch weist dieses Behandlungskonzept weiterhin einen wesentlichen Nachteil auf: noch immer wird der langfristige Erfolg der Therapie zu oft durch die so genannte Transplantatabstoßung gefährdet. Hierbei handelt sich um eine vom Organtransplantat ausgelöste Immunantwort, die zu dessen Zerstörung führt. Die derzeit einzige Möglichkeit eine Abstoßung zu verhindern, ist die Unterdrückung des Immunsystems mit so genannten Immunsuppressiva. Auch wenn diese erstmals in den 60er Jahren des 20. Jahrhunderts erfolgreich eingesetzten Medikamente ständig verbessert werden, bleiben die von ihnen ausgelösten Nebenwirkungen weiterhin ein ernstzunehmendes Problem. Sie unterdrücken die gesamte körpereigene Abwehr, was zum Schutz der Organtransplantate vor Abstoßung gewünscht ist, doch fördern sie hierdurch die Entstehung von Tumoren und Infektionen. Bei der Transplantatabstoßung handelt es sich um eine von CD4+ T-Lymphozyten ausgelöste Immunantwort. Diese Lymphozyten werden von allogenen Peptiden, die von Spender-MHC-Molekülen stammen, über den indirekten Weg der Alloantigenerkennung aktiviert. An der Transplantatabstoßung ist zwar eine Vielzahl von Alloantigenen beteiligt, doch ist es möglich, Peptidantigene zu identifizieren, die einen nachweisbaren Effekt auf die Transplantatabstoßung ausüben. So wurde in der eigenen Arbeitsgruppe die für die Abstoßung allogener Organtransplantate beteiligten MHC (RT1u)-Peptidantigene charakterisiert. Insbesondere die Bedeutung des aus 19 Aminosäuren bestehenden allogenen Peptids P1 für die Alloimmunantwort wurde intensiv untersucht. So weisen P1-spezifische T-Lymphozyten ein ausgeprägtes Th1-Cytokin-Muster auf und beschleunigen die Abstoßung von Wistar-Furth-Organtransplantaten in Lewis-Ratten. Das Ziel dieser Arbeit war die Charakterisierung des T-Zellrezeptor Vb-Repertoires P1-spezifischer T-Lymphozyten mit der Methode des PCR-ELISA. In einem ersten Schritt wurden Thymozyten und T-Lymphozyten unterschiedlicher Lymphknotenstationen untersucht. Thymozyten exprimierten alle 22 TCR Vb-Elemente und einzig TCR Vb14 war überrepräsentiert. Die T-Lymphozyten der cervikalen, mesenterialen, iliakalen und poplitealen Lymphknoten zeigten ebenfalls eine charakteristische Überexpression bestimmter TCR Vb-Elemente. So exprimierten cervikale T-Lymphozyten bevorzugt die TCR Vb-Elemente 2, 6, 8.3 und 16, mesenteriale T-Lymphozyten die TCR Vb-Elemente 2, 4, und 8.1, illiakale T-Lymphozyten die TCR Vb-Elemente 2 und 6 und popliteale T-Lymphozyten die TCR Vb-Elemente 2, 4 und 9. Die Immunisierung mit dem nicht-immunogenen Kontrollpeptid (Autoantigen) Ac führte zu einer leichten Veränderung des T-Zellrezeptor-Repertoires, bei der die TCR Vb-Elemente 14 und 16 überexprimiert waren. Das Adjuvant TiterMax beeinflusste kaum das TCR Vb-Repertoire. Die Immunisierung mit dem allogenen Peptid P1 führte zu einer eindeutigen Beeinflussung des T-Zellrezeptor-Repertoires. Popliteale T-Lymphozyten, die 7 Tage nach Immunisierung analysiert wurden, zeigten ein Repertoire, bei dem die TCR Vb-Elemente 15, 16, 17 und 20 überexprimiert waren. Dieses Repertoire war am Tag 3 nach Immunisierung noch nicht so ausgebildet. Wurden die antigenspezifischen T-Lymphozyten nach ihrer Isolierung mit P1 in vitro restimuliert, so waren in diesem T-Zellrezeptor-Repertoire die TCR Vb-Elemente 8.3, 15, 16 und 20 überexprimiert. Zum Vergleich: in naiven T-Lymphozyten waren die Vb-Elemente 2, 4 und 9 überexprimiert. Damit war es zu einer deutlichen Verschiebung im T-Zellrezeptor-Repertoire antigenspezifischer T-Lymphozyten gekommen, die auf das Peptidantigen P1 zurückzuführen ist. Mit der Methode des PCR-ELISA wurde das T-Zellrezeptor-Repertoire antigenspezifischer T-Lymphozyten bestimmt. Hiermit sind wesentliche Voraussetzungen geschaffen worden, um T-Zellklone zu etablieren und ihre Bedeutung für die Transplantatabstoßung genauer zu untersuchen. / Organ transplantation is an important medical therapy for patients with irreversibly damaged organs. However, this therapeutic intervention has a great disadvantage because the long-term success of organ allografts is still too often endangered by the so called allograft rejection, an immune response directed to the allograft and leading to its destruction. The major approach for the prevention and management of allograft rejection is to suppress the immune system with immunosuppressive agents. These agents were introduced into transplantation medicine in the 1960s and since that time they have been continually improved. However, their side effects remain a seriousness problem because the suppression of the immune defence inhibits the allograft rejection on the one hand but causes infections and increases tumour incidence on the other hand. The allograft rejection is mediated by CD4+ T lymphocytes and the responsible antigens recognized by them are allogenic peptides processed from donor MHC molecules. Although a large number of allgenenic peptides are involved in allograft rejection, it is possible to identify certain peptide antigens involved in allograft rejection. In our group allogeneic peptides from MHC class I molecules from Wistar Furth rats were investigated. The significance of the allogeneic peptide P1, consisting of 19 amino acids, in inducing allograft rejection was analysed in detail. P1-specific T lymphocytes demonstrated a Th1-cytokine dominated profile and accelerated the rejection of allografts in Lewis rats donated by Wistar Furth rats. The aim of this study was to characterise the T cell receptor (TCR) Vb repertoire of P1-specific T lymphocytes with the PCR-ELISA technique. First, thymocytes and T lymphocytes from different lymph nodes were analysed. Thymocytes expressed all 22 TCR Vb elements and only TCR Vb14 was overrepresented. The T lymphocytes of cervical, mesenteric, iliacal und popliteal lymph nodes also demonstrated a certain repertoire of overrepresented TCR Vb elements. In cervical T lymphocytes the expression levels of the TCR Vb elements 2, 6, 8.3 and 16 were increased; in mesenteric T lymphocytes the TCR Vb elements 2, 4 and 8.1; in illiacal T lymphocytes the TCR Vb elements 2 and 6; and in popliteal T lymphocytes the TCR Vb elements 2, 4 and 9. The immunisation with the autoantigen Ac led to a small variation of the TCR Vb repertoire and the TCR Vb elements 14 and 16 were overrepresented. The adjuvant TiterMax did not influence the TCR Vb repertoire. In contrast, the immunisation with the allogeneic peptide P1 clearly influenced the T cell receptor repertoire. Popliteal T lymphocytes analysed 7 days after immunisation demonstrated a TCR Vb repertoire where the TCR Vb elements 15, 16, 17 und 20 were overrepresented. On day 3 after immunisation this repertoire was not yet clearly developed. In P1-specific T lymphocytes restimulated in vitro the expression levels of the TCR Vb elements 8.3, 15, 16 and 20 were increased. In comparison, in naïve T lymphocytes the TCR Vb elements 2, 4 and 9 were overrepresented. These results underline that the immunisation with peptide P1 induces a characteristic TCR Vb repertoire. The TCR Vb repertoire of P1-specific T lymphocytes was analysed with the PCR-ELISA technique. The determination of the T cell receptor repertoire is a prerequisite to establish T cell clones and to analyse their involvement in allograft rejection.

Os objetivos desse estudo foram: 1) Padronizar a pesquisa do anti-tTg, comparando-o com o anticorpo antiendomísio (AAE) e 2) Avaliar as interações da tTg com a fibronectina. 49 celíacos e 124 controles com AAE negativo foram avaliados. O AAE foi pesquisado por imunofluorescência indireta e a reatividade contra a tTg e a fibronectina por ELISA in house e com kits comerciais. O antitTg foi positivo em 46,9% e 100% dos celíacos com o ELISA in house e com kits comerciais, respectivamente. A adição de fibronectina não melhorou a sensibilidade do ELISA. Em conclusão: a detecção do antitTg por ELISA apresenta percentual elevado de falso-positivos, não podendo substituir a pesquisa do AAE / The aims of the current study were: to standardize the detection of anti-tTg antibodies, comparing them with antiendomysial antibodies (EMA) and to assess the interaction of tTg with fibronectin. 49 celiac patients and 124 controls were enrolled. EMA was detected by indirect immunofluorescence reaction and tTg and fibronectin reactivity by in house ELISA and with commercially available kits. Seropositivity to anti-tTG was found in 46.9% and 100% of patients by the in house technique and by commercial kits, respectively. Fibronectin addition did not improve the ELISA sensibility. In conclusion, ELISA for anti-tTG detection has a high rate of false positive results and does not replace EMA

INTRODUÇÃO: Apesar de ser a droga de primeira escolha na prevenção da hemorragia pós-parto, o uso da ocitocina em cesarianas permanece empírico. O objetivo deste estudo foi dosar a ocitocina sérica após a administração profilática de diferentes regimes de ocitocina em pacientes submetidas à cesariana eletiva. MÉTODOS: 30 pacientes que se apresentaram para cesariana eletiva foram randomizadas para receber ocitocina intravenosa, após o clampeamento do cordão umbilical, nos seguintes grupos: G1 (n=9): 10 UI de ocitocina infundidas em 30 minutos (0,33 UI/min), G2 (n=11): 10 UI de ocitocina infundidas em 3 minutos e 45 segundos (2,67 UI/min) e G3 (n=10): 80 UI de ocitocina infundidas em 30 minutos (2,67 UI/min). Este estudo foi encoberto para as pacientes e para os cirurgiões. A avaliação do tono uterino foi realizada pela equipe cirúrgica e a dosagem da concentração sérica de ocitocina foi feita pela técnica de enzimoimunoensaio (ELISA), antes da anestesia (T0) e nos tempos 5 (T5), 30 (T30) e 60 (T60) minutos após o início da infusão da ocitocina. RESULTADOS: Os níveis de ocitocina sérica (média ± erro padrão, ng/mL) foram semelhantes entre os grupos em T0 (0,062 ± 0,021; 0,039 ± 0,019 e 0,067 ± 0,041; respectivamente, p = 0,76) e em T60 (0,648 ± 0,257; 0,356 ± 0,257 e 0,683 ± 0,257; respectivamente, p = 0,58). G3 apresentou níveis maiores de ocitocina que G1 em T5 (3,651 ± 0,741 versus 0,709 ± 0,268; p = 0,01). Em T30, G3 apresentou níveis de ocitocina sérica maiores que G1 (6,190 ± 1,195 versus 1,174 ± 0,375; p < 0,01) e, também, que G2 (6,190 ± 1,195 versus 0,411 ± 0,206; p < 0,01). Os parâmetros hemodinâmicos foram semelhantes entre os grupos. O tono uterino foi considerado satisfatório em todos os intervalos estudados e não houve a necessidade de utilização de uterotônico complementar. CONCLUSÃO: Foram demonstradas dosagens séricas de ocitocina por ELISA em gestantes submetidas à cesariana eletiva. A administração de 80 UI de ocitocina em 30 minutos resulta em níveis séricos de ocitocina maiores que os outros dois métodos de administração aos 5 e 30 minutos, porém, estas concentrações não diferem aos 60 minutos / BACKGROUND: The use of oxytocin to prevent postpartum hemorrhage after elective cesarean delivery still remains empirical. The purpose of this study was to determine oxytocin serum levels following differents regimens of prophylactic oxytocin administration in pregnant women undergoing elective cesarean delivery. METHODS: 30 healthy pregnant patients were randomized to receive intravenous oxytocin, after clamping of the umbilical cord, into the following groups: G1 (n=9), 10 IU of oxytocin infused over 30 minutes (0.33 IU/min); G2 (n=11), 10 IU of oxytocin infused over 3 minutes and 45 seconds (2.67 IU/min) and G3 (n=10), 80 IU of oxytocin infused over 30 minutes (2.67 IU/min). Both patient and surgeon were blinded to the study group allocation. Uterine tone was assessed by palpation by the surgeon. Serum oxytocin concentration was determined by enzyme immunoassay (EIA) before anesthesia (T0) and at 5 (T5), 30 (T30) and 60 (T60) minutes following the start of oxytocin infusion. RESULTS: Serum oxytocin levels (mean ± standard error, ng/mL) were similar in the groups at T0 (0.062 ± 0.021, 0.039 ± 0.019 and 0.067 ± 0.041, respectively, P = 0.76), and T60 (0.648 ± 0.257, 0.356 ± 0.257 and 0.683 ± 0.257, respectively, P = 0.58). G3 presented higher serum oxytocin than G1 at T5 (3.651 ± 0.741 versus 0.709 ± 0.268, P = 0.01). At T30, serum oxytocin levels of G3 were higher than G1 (6.190 ± 1.195 versus 1.174 ± 0.375, P < 0.01) and also than G2 (6.190 ± 1.195 versus 0.411 ± 0.206, P < 0.01). Hemodynamic data were similar in all groups. Uterine tone was considered satisfactory in all intervals studied and no additional uterotonic agent was needed. CONCLUSION: We demonstrate serum oxytocin determinations by EIA in healthy pregnant women presented for elective cesarean delivery. Administering 80 IU in 30 min results in higher serum oxytocin levels at 5 and 30 min than the other two methods of oxytocin administration, but the concentrations did not differ at 60 min

HCMV is a common viral pathogen that infects most of the world's population by early adulthood. It is typically asymptomatic in immunologically healthy individuals but causes severe disease in immunocompromised patients and congenitally infected infants. HCMV glycoproteins are highly polymorphic, and various types of associations have been suggested between glycoprotein types and the pathogenicity of the virus. Several studies on viruses other than HCMV have related the glycosylation of the viral glycoproteins to virulence. This project aimed to determine whether there is a robust relationship between the individual glycoprotein sequence and its glycosylation, how this influences the growth characteristic of the virus and whether this is related to its pathogenicity. Glycosylation patterns of 89 clinical specimens of different infection categories and specimen types were correlated with genetic sequence alterations of the virus glycoproteins (gB, gH, gL, gM, gN, gO), followed by determining whether mutation results in specific changes in glycosylation. The aim was approached using a cell culture model and a quantitative lectin-based assay (ELLA). A significantly increased glycosylation level for the following genotypes: mixed gH, gN4a, gO4, mixed gL was detected. Whereas a decreased pattern was found to be associated with gH1, gH2, gN3a, gO1a and gL2 genotypes (P < 0.05). Glycoproteins of strains isolated from respiratory specimens were significantly highly glycosylated compared to the blood and urine samples, and from blood specimens compared to the urine samples (P < 0.05). Furthermore, strains from congenitally infected infants and urine samples had a significantly higher growth rate than others tested. No direct association between the virus growth and its virulence was found. These findings demonstrate that glycosylation of glycoproteins in HCMV is affected by the glycoprotein polymorphisms and signifies a potentially important mechanism for avoidance of antibody-mediated neutralization, which, in turn, facilitates HCMV pathogenicity. This phenomenon requires further study and may have application for the selection of novel targets for diagnosis, vaccine development and other preventive measures to combat diseases caused by this virus.

INTRODUÇÃO: Apesar de ser a droga de primeira escolha na prevenção da hemorragia pós-parto, o uso da ocitocina em cesarianas permanece empírico. O objetivo deste estudo foi dosar a ocitocina sérica após a administração profilática de diferentes regimes de ocitocina em pacientes submetidas à cesariana eletiva. MÉTODOS: 30 pacientes que se apresentaram para cesariana eletiva foram randomizadas para receber ocitocina intravenosa, após o clampeamento do cordão umbilical, nos seguintes grupos: G1 (n=9): 10 UI de ocitocina infundidas em 30 minutos (0,33 UI/min), G2 (n=11): 10 UI de ocitocina infundidas em 3 minutos e 45 segundos (2,67 UI/min) e G3 (n=10): 80 UI de ocitocina infundidas em 30 minutos (2,67 UI/min). Este estudo foi encoberto para as pacientes e para os cirurgiões. A avaliação do tono uterino foi realizada pela equipe cirúrgica e a dosagem da concentração sérica de ocitocina foi feita pela técnica de enzimoimunoensaio (ELISA), antes da anestesia (T0) e nos tempos 5 (T5), 30 (T30) e 60 (T60) minutos após o início da infusão da ocitocina. RESULTADOS: Os níveis de ocitocina sérica (média ± erro padrão, ng/mL) foram semelhantes entre os grupos em T0 (0,062 ± 0,021; 0,039 ± 0,019 e 0,067 ± 0,041; respectivamente, p = 0,76) e em T60 (0,648 ± 0,257; 0,356 ± 0,257 e 0,683 ± 0,257; respectivamente, p = 0,58). G3 apresentou níveis maiores de ocitocina que G1 em T5 (3,651 ± 0,741 versus 0,709 ± 0,268; p = 0,01). Em T30, G3 apresentou níveis de ocitocina sérica maiores que G1 (6,190 ± 1,195 versus 1,174 ± 0,375; p < 0,01) e, também, que G2 (6,190 ± 1,195 versus 0,411 ± 0,206; p < 0,01). Os parâmetros hemodinâmicos foram semelhantes entre os grupos. O tono uterino foi considerado satisfatório em todos os intervalos estudados e não houve a necessidade de utilização de uterotônico complementar. CONCLUSÃO: Foram demonstradas dosagens séricas de ocitocina por ELISA em gestantes submetidas à cesariana eletiva. A administração de 80 UI de ocitocina em 30 minutos resulta em níveis séricos de ocitocina maiores que os outros dois métodos de administração aos 5 e 30 minutos, porém, estas concentrações não diferem aos 60 minutos / BACKGROUND: The use of oxytocin to prevent postpartum hemorrhage after elective cesarean delivery still remains empirical. The purpose of this study was to determine oxytocin serum levels following differents regimens of prophylactic oxytocin administration in pregnant women undergoing elective cesarean delivery. METHODS: 30 healthy pregnant patients were randomized to receive intravenous oxytocin, after clamping of the umbilical cord, into the following groups: G1 (n=9), 10 IU of oxytocin infused over 30 minutes (0.33 IU/min); G2 (n=11), 10 IU of oxytocin infused over 3 minutes and 45 seconds (2.67 IU/min) and G3 (n=10), 80 IU of oxytocin infused over 30 minutes (2.67 IU/min). Both patient and surgeon were blinded to the study group allocation. Uterine tone was assessed by palpation by the surgeon. Serum oxytocin concentration was determined by enzyme immunoassay (EIA) before anesthesia (T0) and at 5 (T5), 30 (T30) and 60 (T60) minutes following the start of oxytocin infusion. RESULTS: Serum oxytocin levels (mean ± standard error, ng/mL) were similar in the groups at T0 (0.062 ± 0.021, 0.039 ± 0.019 and 0.067 ± 0.041, respectively, P = 0.76), and T60 (0.648 ± 0.257, 0.356 ± 0.257 and 0.683 ± 0.257, respectively, P = 0.58). G3 presented higher serum oxytocin than G1 at T5 (3.651 ± 0.741 versus 0.709 ± 0.268, P = 0.01). At T30, serum oxytocin levels of G3 were higher than G1 (6.190 ± 1.195 versus 1.174 ± 0.375, P < 0.01) and also than G2 (6.190 ± 1.195 versus 0.411 ± 0.206, P < 0.01). Hemodynamic data were similar in all groups. Uterine tone was considered satisfactory in all intervals studied and no additional uterotonic agent was needed. CONCLUSION: We demonstrate serum oxytocin determinations by EIA in healthy pregnant women presented for elective cesarean delivery. Administering 80 IU in 30 min results in higher serum oxytocin levels at 5 and 30 min than the other two methods of oxytocin administration, but the concentrations did not differ at 60 min

Aberrant expression of short non-coding micro RNAs (miRNA) in many human diseases, along with remarkable stability in physiological media, has made them attractive clinical biomarkers. In particular, miRNA-122 is substantially elevated in plasma of patients with established drug-induced liver injury and can also be used to identify early liver injury when current markers, such as alanine aminotransferase (ALT), still show normal levels. The development of a rapid test for miRNA-122 e.g. in drug poisoning would allow earlier and more sensitive clinical diagnosis of liver injury. Nucleic acids are traditionally analysed by polymerase chain reaction (PCR), which has a high degree of sensitivity but suffers from high cost and is prone to sample contamination. The aim of this project is to develop a PCR free method to directly detect miRNA- 122 in biological samples using SMART technology. The SMART technology takes advantage of dynamic chemistry for sequence specific recognition of nucleic acids using aldehyde-modified nucleobases (SMART nucleobases), and target-complementary peptide nucleic acid (PNA) probe containing an “abasic” position (so called modified PNA probe). In this study, this unique detection method was used in a fluorescent detection with the use of light up probes, which are probes with an environmental dye as nucleobase; a FRET system was also designed to allow the discrimination between perfect match target and mismatched one. The SMART technology was also transferred onto magnetic beads to develop an ELISA like assay allowing sensitive and rapid detection of single stranded DNA mimic of the miRNA-122. With its potential PCR free approach, this easily adapted platform promises to transform and expand routine clinical diagnostic testing and screening for circulating miRNAs.

see pdf

Increased reactive oxygen species (ROS) have been reported to be at the centre of various diseases. Although several reports have implicated elevated levels of ROS in the pathogenesis of diabetes mellitus, the early detection of ROS is still not attainable. This limitation causes difficulty in the early diagnosis of ROS related disorders. The presence of high levels of ROS was reported to result in differential expression of antioxidant genes involved in protecting cells from their deleterious effects. Among the antioxidant genes that are expressed, it was postulated that expression of metallothioneins (MTs) are also induced. MTs are low molecular weight, cysteine-rich proteins involved in metal homeostasis and reported to harbour antioxidant function. The aim of this investigation was to explore MTs as biomarkers for elevated levels of ROS in whole blood of type 2 diabetic (T2D) individuals. The level of ROS in diabetic, non-diabetic as well as individuals at risk of developing T2D was determined via the use of biochemical assays. Real-Time PCR was utilised to analyse the expression of MTs and the presence of MT proteins was analysed via the ELISA. In this study it was observed that diabetic individuals had elevated levels of ROS. However, no significant difference in the expression of MTs and the presence of MT proteins between the diabetic and non-diabetic individuals was observed. In vitro experimental conditions indicated that MT expression is induced by elevated levels of ROS. In pathological conditions the ROS-dependent induction of MT expression needs to be elucidated further. It therefore can be suggested that MTs can not yet be utilised as biomarkers for the detection of elevated levels of ROS in pathological conditions with ROS aetiology. This investigation also highlights the fact that blood is not an optimal medium in which this objective can be attained. / Thesis (Ph.D. (Biochemistry))--North-West University, Potchefstroom Campus, 2005.

Mycoplasmas conform most closely with the theoretical concept of 'minimum cells', existing as the smallest, free-living organisms capable of self-replication. They survive as parasites of plants, insects, animals or humans, with the most common human colonising species being Mycoplasma hominis. M. hominis has been characterised as a human pathogen responsible for a variety of infections, which pose a significant threat particularly to immunocompromised patients and neonates. However little has been elucidated about the cell physiology and molecular structure of this organism. Of interest to this study were the investigation of the heat shock response of M. hominis and the diagnostic assays used for its detection. The heat shock response is a ubiquitous physiological feature of all organisms and displays unprecedented conservation. This phenomenon is particularly evident in the 70 kDa family of heat shock proteins (hsp70) which exhibits a high degree of homology between different species. The hsp70 gene from M. hominis was cloned and preliminary partial sequencing indicated the similarity with other hsp70 homologs. The regulation of hsp70 expression at the transcriptional and translational levels was investigated. The level of hsp70 mRNA was found to increase correspondingly in response to heat shock, more visibly than the level of hsp70 protein. However imrnunochemical studies of the M. hominis hsp70 translation product demonstrated further the homology with other species. To facilitate rapid diagnosis of M. hominis infections, a PCR ELISA diagnostic assay was developed and optimised. The amplification of a conserved region of the M. hominis 16S rRNA gene was linked to subsequent hybridisation to an appropriate capture probe in a microtiter plate format. The sensitivity of the assay was comparable to other molecular assays although the PCR ELISA produces more rapid results and is less labour intensive. / Thesis (M.Sc.)-University of Natal, Pietermaritzburg, 1998.